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(Toh Keng Kiat 89). Robert Klein, head of the 2004 Proposition 
71 campaign to fund stem cell research in California, stated that 
even as we wait for stem cells to be “perfected, they’ll dispense 
potent medicine—hope” (McManus 159). Unfortunately, we 
can never be certain of a “correct” answer when discussing 
ethical questions and morals; we can only do what is best for 
the majority. A majority of our population does stand to profit 
from stem cell research, and “helping many, many individuals 
is justification for taking a single cell […] and using it to benefit 
more individuals” (McManus 170). However, stem cell research 
progress has been stalled in our nation since critics of the 
research—President Bush included—wield more power over 
science than the scientists themselves because of political, 
legal, and ethical debates freezing the progress of researchers.
 Conservatives opposed to embryonic stem cell research 
favor a ban on the use of human embryos for research, arguing 
that “human beings in their earliest stages have the same right 
not to be killed that children and adults do” (“Stem” 12). These 
individuals base their beliefs on a literal interpretation of the 
Bible (“whatever you did [to] one of the least of these […], you 
did [to] me”), with fears of organ farms and indestructible 
cloned armies fueling their crusade (Concordia, Matt. 25.40b). A 
prominent theory among naysayers is that of the classic slippery 
slope. Opponents to stem cell research fear “that allowing 
this would put us on a slippery slope towards reproductive 
cloning” (Holm 500). In the UK and “a number of other 
European countries,” the “political reaction to the perceived 
slippery slope […] is seen as a possible threat to the positive 
development of stem cell research,” while being perceived by 
the U.S. government as a “possible tool to justify the prohibition 
of stem cell research […] as part of a more comprehensive ban 
on all kinds of human cloning” (Holm 501). What challengers 
to stem cell research fail to recognize, however, is that “‘the 
potential to become something (or someone) is hardly the 
same as being something (or someone)’” (qtd. in McManus 
169). Jonathan D. Moreno, Kornfeld Professor and Director of 
the Center for Biomedical Ethics at the University of Virginia, 
summarizes the “standard argument” for the employment 
of “the hundreds of thousands” of unused embryos still in 
 Humpty-Dumpty sat on a wall; Humpty-Dumpty had a 
great fall. All the king’s horses and all the king’s men couldn’t 
put Humpty together again…but stem cells sure could. However, 
American eagerness to formulate generally uneducated opinions 
regarding sophisticated and complex issues such as stem 
cell research often scribes disaster for the minds behind the 
technology. This, when coupled with government willingness to 
pass legislation representing “the people” (however uninformed), 
leads to unnecessary restrictions on a powerful medical tool 
like stem cell advancement. Because American society as a 
whole—including the government—is ignorant on scientific 
matters such as stem cell research, only experts at the helms of 
privately funded corporations should make decisions regarding 
this issue. The federal government should lift its restrictions, 
thereby permitting the pursuit of both embryonic and adult 
stem cell research, and support current endeavors toward 
the collection of umbilical cord blood for research purposes, 
or the United States will fall further behind other nations.
 By definition, “a stem cell is a non-differentiated cell 
that can divide and multiply in its undifferentiated state, but 
which can also give rise to more specialized differentiated 
cells” (Holm 494). Incredible controversy has arisen in the U.S. 
specifically over embryonic stem cell research. Human embryos 
contain “the most powerful stem cells,” as these totipotent cells 
“have the potential of transforming to any type of cell” and 
therefore contain by far the most potential of the three types 
of stem cells—embryonic, adult, and umbilical cord blood cells 
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Stem Cell Research and Cures Initiative came many proponents 
of this amendment, using scientific data and the experiences of 
others as support for their standing. Over 100 non-profit patient 
and medical groups supported a “yes” vote on Amendment 
2, including the American Association for Cancer Research, 
American Diabetes Association, Christopher Reeve Foundation, 
Muscular Dystrophy Association, and Society for Women’s 
Health Research (Why). The medical conditions for which 
stem cells could provide cures “affect hundreds of thousands 
of Missourians—including a child, parent, or grandparent in 
over half of all Missouri families” (Why). It is those hundreds of 
thousands of people in one state alone (not to mention the rest 
of the nation, the world, and the afflicted yet to come) that justify 
using tiny, non-human bunches of cells grown in tubes and 
dishes to assist in the discovery of cures for diseases inflicting 
pain and death on living, breathing, feeling human beings.
 Jeff McCaffrey is a business major at the University of 
Missouri-Kansas City. He played football as a college freshman 
at the U.S. Air Force Academy when he was paralyzed in a 
car accident. Now in a wheelchair, he is “rallying students” 
and has helped found the Student Society for Stem Cell 
Research, UMKC chapter, the “first student-organized stem 
cell advocacy group in Missouri,” for the “cause that may have 
him walking again” (“UMKC”). The mission of the SSSCR is “to 
educate, advocate, and act on public policy affecting medical 
stem cell research” (“UMKC”). Similarly, retired Missouri U.S. 
Army veteran Colonel Stanley D. Brown remarked during 
the campaign for the Missouri Stem Cell Research and Cures 
Initiative, “When I talk with injured soldiers back from Iraq 
and Afghanistan, sometimes the only smile I receive is when I 
speak of the medical research being done to repair or replace 
damaged spinal cord nerves,” the same kind of treatment that 
could in the future help Jeff McCaffrey walk once again (Why). 
Matt LaVanchy, a fire fighter, also reasons in favor of stem cell 
research with the following: “Stem cells could provide cures 
for diseases like muscular dystrophy and new treatments for 
severe burn injuries that affect thousands of fire victims and 
fire fighters” (Why). They—those suffering with muscular 
dystrophy, Alzheimer’s, sickle cell disease, ALS, lung diseases, 
fertility clinics: The embryos “could be freely donated, and 
they will never be implanted so will never be in a position 
to continue to develop” (Moreno 3). He also explains critics’ 
assertions that “there is in this argument a suppressed appeal 
to a notorious premise that these leftover embryos ‘will die 
anyway,’” somehow thereby associating “the feared massacre of 
human embryos in fertility clinics with a previous holocaust,” 
but an embryo becomes a human being and is given life in 
a mother’s womb, not in a test tube or Petri dish (Moreno 3).
 On November 7 of last year (2006), Missouri voters passed 
Amendment 2, the Missouri Stem Cell Research and Cures 
Initiative, with support from 51.1 percent of the electorate (about 
45,000 votes) despite the pronounced efforts of those opposed. 
One Lutheran church’s newsletter told the members of its 
congregation to vote against the amendment in the election, 
describing the wording of the initiative as “deceitful” and citing 
Proverbs 15:4 as a supporting verse: “‘The tongue that brings 
healing is a tree of life, but a deceitful tongue crushes the spirit’” 
(St. Paul). In fact, the main arguments against Amendment 2 
came from churches and specifically targeted the vocabulary of 
the initiative with regard to cloning and “ambiguous language 
about unborn human life (e.g. ‘the product of fertilization’),” 
stating it would “[open] the door for unlimited taxpayer funds 
to be used for the cloning and destruction of human embryos” 
(St. Paul). The Missouri Roundtable for Life called the cloning 
initiative “the boldest attempt ever to highjack the legitimate 
processes, procedures, and functions of representative 
government in Missouri,” further asserting that “its basic 
mechanism is a language structure […] designed to defeat the 
casual reader by reversing reasonable inferences about the 
text in subsequent subsections” (St. Paul). The main point of 
interest in this particular pamphlet and countless other pieces 
of religious propaganda against the amendment is the lack of 
definition of the origin of life (when it begins, what is considered 
a “human being,” etc.) or a substantial argument against stem 
cell research itself, topics which many individuals debate. The 
difficulty lies not in stating one’s position but in defending 
that position with solid facts, which the church failed to do.
 Along with substantial campaigns against the Missouri 
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through SCNT reproduce without differentiating and then 
direct their cellular development, thereby eliminating some of 
the hullabaloo surrounding the use of actual human embryos 
(Cohen 240). This could be achieved through therapeutic 
cloning, or stem cell expansion. SCNT is, after all, part of a 
broader area of study known as “human research cloning.” Lest 
we turn ghostly pale at the word “clone,” interim president and 
neuroscientist Zach W. Hall of the University of California, San 
Francisco School of Medicine assures us that “no, we’re [not 
cloning human beings]; we’re taking the cells out at a very, very 
early level of development and cloning cells” (Lehrman 40). 
When stem cells divide, they “create one copy of themselves 
(daughter cells), and start differentiating into specialized cells” 
(Toh Keng Kiat 92). Stem cell expansion would “create daughter 
cell after daughter cell without also differentiating” (Toh Keng 
Kiat 92). Nonetheless, additional ethical queries arise from the 
possible abuse of cloning’s extensive replication capabilities.
 Here we make the distinction between “reproductive 
cloning (to make a baby that’s genetically identical to the 
donor), which almost no one favors, or therapeutic cloning 
(to isolate and harvest its stem cells) to advance the field of 
regenerative medicine” (McManus 158). We cannot prohibit 
all cloning “just because its therapeutic applications could 
be misused. Even Michael Jackson’s face doesn’t get plastic 
surgeons arrested” (McManus 169). In 1998 “researchers at the 
University of Wisconsin published a method for deriving and 
culturing human embryonic stem cells indefinitely,” making 
possible the creation of “stable human stem cell lines” and 
“[generating] (in principle) unlimited quantities of any particular 
embryonic stem cell” (Holm 494). The results of therapeutic 
cloning would be these stem cell lines, “something that is 
self-renewing, that you can perpetuate indefinitely,” though 
“researchers will need hundreds—possibly thousands—of 
lines to provide genetic matches for the entire population” 
(Bruck 13; McManus 161). Stem cell lines would allow for both 
the standardization of “research into human stem cells” and 
the creation of “reproducible stem cell therapies” (Holm 494). 
Today, however, only a few are in existence in the United States.
 An inevitable consequence of the attempted development 
or diabetes; those who are paralyzed; burn victims; and so many 
more—are the ones we think about when we think of stem cell 
research and all it has to offer (Why). The bundles of cells in 
a laboratory are not people; they are not even comparable.
 The potential to develop into a life is hardly the same as a 
life itself, evidenced in the process of somatic cell nuclear transfer 
(SCNT), part of the “human research cloning protocols” of several 
acclaimed scientific teams from around the world (Hyun and 
Jung 34). In this procedure, the nucleus of an unfertilized human 
egg is replaced with the nucleus of an ordinary patient-specific 
human cell and used to “develop a blastocyst-stage embryo that 
is genetically identical to the patient cell donor” (McManus 158, 
Hyun and Jung 34). These altered human stem cells are then 
cloned (McManus 158). However, “like the stem cell [‘soup’] more 
generally, the idea of using the products [human blastocysts] of 
SCNT to generate lines of human embryonic stem cells has 
thrust a remarkably esoteric matter into the political scene” 
(Moreno 3). When broken down into its basic parts, however, 
the issue becomes uncomplicated and more black-and-white.
 Fundamentally, this newest breakthrough clearly poses 
an unembellished challenge to the conservatives’ position 
that embryonic stem cell research ends human lives. With 
the explanation that “every human cell contains the genetic 
information to create a new human being, the old arguments 
for preserving ‘unique’ human embryos fade away” (Singer 
40). Obviously, “‘if mere potentiality to develop into a human 
being is enough to make something morally human, […] then 
every human cell has a special or inviolable moral status, a 
view that is patently absurd’” (McManus 170). The opposition, 
however, argues that “the use of a neutral expression [somatic 
cell nuclear transfer] deliberately obfuscate[s] what [is] ‘really 
going on’” and accused the California Stem Cell Research 
Initiative sponsors of “deception,” though the name of the 
process does actually describe exactly what is “really going on” 
(Moreno 3). Debates on the power and philosophy of language 
should be left out of science. We have the abilities to think, 
learn, and create in order to use them, not sit idly on them.
 Another goal of embryonic stem cell research has 
been to discover a method to make these stem cells created 
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to the procedure. For that reason, the risks of egg harvesting 
should not factor into the debate over stem cell research as long 
as women are receiving a full-disclosure risk-benefit analysis 
before undertaking such a commitment. These women are 
aiding in the development of therapies that may someday save 
their own lives. When much of the contentious work such as 
settling debates like this one is finished, scientists can continue 
progressing toward cures and treatments, uninterrupted.
 However, scientists must first finish this litigious work 
before they can move forward with therapies, and government 
restrictions under President Bush’s plan are seriously inhibiting 
their progress.  President Bush believes that embryonic stem cell 
research crosses a moral boundary, stating he “oppose[s] federal 
funding for stem cell research that involves destroying living 
human embryos” (“AASP”). In a feeble attempt at compromise, he 
announced his plan on August 9, 2001, limiting federal funding 
to 64 “genetically diverse” lines he claimed existed worldwide, 
created before the implementation of his policy (“AASP,” “Time” 
11a). By 2004, many called for a reform of the President’s policy as 
reports concurred “the original number of embryonic stem cell 
lines deemed available for federal research in August 2001 had 
been overestimated and many of those cell lines were perhaps 
unsuitable for research,” all having been “tainted by animal 
products used to help them grow in the laboratory. They may be 
useless or even dangerous in treating humans, a study published 
in January’s Nature Medicine found” (“AASP,” “Time” 11a). 
 In addition, they are far from “genetically diverse,” most 
being from “people who tend to use in vitro clinics—the white, 
the infertile, the affluent” (McManus 161). While the affluent 
may at first be the only ones with the means to afford stem cell 
research treatments and therapies (and therefore be unaffected 
by the limited number of therapies with the potential to develop 
now), one must take into consideration the fact that these are 
more than cosmetic issues. As with many types of cancer, as 
treatments are more common and better understood for the 
often life-and-death diseases embryonic stem cell research can 
address, insurance and individuals will be able to pay for them. 
They could at the minimum be an option, but the President, 
in his patchy comprehension of the subject matter on which 
of viable stem cell lines is the need for ova. Even for the process 
of somatic cell nuclear transfer, many unfertilized eggs are 
required, just as in more common and accepted fertility treatment 
procedures. The result of this need for ova is the “harvesting 
of multiple eggs,” achieved through ovarian stimulation, “an 
invasive and uncomfortable two-stage process requiring 
many clinic visits, multiple injections of hormones, and minor 
surgery,” at the end of which the “mature eggs are then collected 
[…] for use in in vitro fertilization or in research” (Beeson 574). 
This can be harmful to the women who undergo the process, 
which has led to an occasionally unenthusiastic conclusion.
 A number of individuals fear that “egg harvesting” is 
becoming a serious problem and is “threatening [to] women’s 
health” (Beeson 573). Young women are “being asked to donate or 
sell their ova, not only for use in fertility clinics, but increasingly 
for non-clinical use in experimental cloning research” (Beeson 
573). Egg collection for stem cell research is “being conducted 
in the context of an international race for dominance in—and 
commercialization of—the production of embryonic stem cells 
and related products,” which some do not judge to be a defensible 
rationale for the process considering the alleged threats to 
women’s health in egg harvesting practices (Beeson 573). 
 These individuals believe the “risks of egg harvesting 
[…] do not receive adequate attention” but are instead obscured 
by “a research climate marked by conflicts of interest; the 
misleading use of language to describe research goals; and a 
commercial push that may lead to the exploitation of young 
women” (Beeson 573). The “conflicts of interest” refer to the 
fact that “some physicians who harvest eggs are also involved in 
stem cell research,” a problem when “clinicians have an interest 
in obtaining their eggs” (Beeson 574). Some also feel that the 
emphasis in opposition to embryonic stem cell research should 
center less on “the moral status of the embryo” and more on “other 
important ethical issues raised by women’s health advocates,” 
such as egg harvesting. The fact of the matter is these women are 
going to make that exceedingly personal decision based on their 
own individual financial situations, beliefs, and wishes (Beeson 
574). Those are variables for which no physician can account 
or alter independently of the woman willing to submit herself 
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treatment” (Toh Keng Kiat 92). Scientists are therefore searching 
for a way to increase sample size without altering the cells at all. 
They may have found their answer in the technology of Boston-
based Cyomatrix LLC, whose “core technology is a unique, 
patented, three-dimensional cell growth bimetallic matrix 
called Cyomatrix, a proven platform for cell growth” (Toh Keng 
Kiat 92). The Cyomatrix material “looks and feels like bone 
marrow,” in which stem cells “normally reside and expand” and 
may be useful for enhancing “production of human T-cells, a 
critical component of the immune system” (Toh Keng Kiat 92). 
The abilities of the material have “implications in treatments 
for cancers, immune disorders, viral or bacterial infections, and 
other conditions that are today proving drug resistant” (Toh 
Keng Kiat 92). Still, adult stem cell and umbilical cord blood 
stem cell transplantation each present problems, but even 
with their disadvantages, as of mid-2003, 72 diseases, including 
leukemia and Hodgkin’s disease, were deemed treatable with 
them, which when compared to 45 in 2002 is a promising statistic 
(Toh Keng Kiat 90). Nevertheless, treatments developed from 
umbilical cord blood and adult stem cells compose less than 
half of the number of diseases embryonic stem cell research 
would address, among them various forms of cancer, diabetes, 
cardiovascular disease, rheumatoid arthritis, spinal cord 
injuries, autoimmune disease, allergies, and neurodegenerative 
diseases such as Parkinson’s and ALS (Bruck 21; “Disease” 
787; Passier 11). First, however, the debate must be settled 
before we can use these technologies to their fullest potential.
 The United States should not be willing to let a 
controversy such as the one presently enshrouding embryonic 
stem cell research stall our scientific progress, regardless of 
the limited benefits we are reaping from the two unrestricted 
collection methods. In the past, “it was […] against the law to 
examine dead bodies to help our understanding of ourselves” 
(Cohen 240). Another obstacle comes with the fact that many 
Americans are unaware of the various stem cell collection 
techniques and the ensuing research, which often leads to 
tenuous scorn or dismissal of this developing medical tool. 
The phrase “stem cell research” has, in fact, become a false 
substitute for embryonic stem cell research because of the 
he unhesitatingly adjudicated a conclusive verdict, has built 
an impenetrable Great Wall for American scientists, needlessly 
handcuffing them with an absence of utilizable stem cell lines.
 Fortunately, embryonic stem cell research is not the 
only type of collection method available today; adult stem cells 
are a second alternative. These more “‘traditional’” cells “are 
collected from the bone marrow and peripheral or circulating 
blood” of the person needing the treatment or transplant “so 
as to avoid rejection” (Toh Keng Kiat 89; Cohen 240). The chief 
advantage of adult stem cell research is the “diminished or 
minor ethical concerns expressed by most individuals,” but 
this merely masks greater worries of decreased possibilities 
for both the research and the nation (Cohen 240). Adult 
stem cells are much less versatile than embryonic; therefore, 
scientists are certain that “embryonic stem cells will have 
broader therapeutic applications” (Madden 34). Moreover, 
adult stem cells are “difficult to maintain […] in long term 
culture,” further tapering their potential, yet even the narrow 
applications of adult stem cell research have made it valuable 
(Cohen 240). Nonetheless, embryonic stem cell research 
clearly stands to benefit a significantly larger group of people.
 A third and relatively new means of stem cell collection 
is umbilical cord (or placenta) blood. When the baby is born, 
the doctor extracts the blood still present in the umbilical 
cord and placenta (Toh Keng Kiat 90). The blood is then 
“cryogenically stored for future use” (Toh Keng Kiat 90). 
Like adult stem cells, however, umbilical cord blood stem 
cells are “multipotent,” i.e., incapable of “[generating] all cell 
types” (Toh Keng Kiat 89). In addition, “the cost would be 
phenomenal” and its justification questionable “considering 
the very small proportion of placentas that would be used 
ultimately” (Cohen 240). Another disadvantage of cord blood 
stem cells is because of their relative primitiveness, “the 
engraftment process takes longer, leaving the patient receiving 
the transplantation at risk of infection for a longer period of 
time” (Toh Keng Kiat 91). This could prove fatal in certain 
cases, thereby defeating the total purpose of such a treatment.
 One final problem with umbilical cord blood collection 
is the limited sample size, “usually barely enough for just one 
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way. Popular media, with all its scandalous exposés, is in a way 
sheltered. Celebrities’ newest cosmetic surgeries often trump 
science because it clears both the reporter’s and the average 
person’s head with a healthy margin. We tend to brush science 
off as “boring” or “unimportant” until it affects us personally. 
We sometimes take advantage of the opportunities afforded us 
and leave it to someone else to educate us instead of “home-
schooling” ourselves. In all actuality, “a true democracy cannot 
exist without a fully and accurately informed voting public” 
(Missouri). This illustrates the ironic ignorance of Americans, 
though not all accountability lies with the media and the public.
 In addition to these individuals who neglect to take 
a step beyond popular media and inform themselves about 
topics ranging from potentially useless or even detrimental 
health supplements they are currently taking to pressing 
scientific issues like stem cell research, a weighty portion of 
the blame descends on scientists themselves. Undoubtedly, 
much more is at stake than the size of one’s thighs or a flawless 
complexion with respect to stem cell research. The final step 
of the scientific method is to report and share results, yet 
the experts often express timidity at making their findings 
known. In the United States, “scientists are still doing ground-
breaking work with mouse stem cells, […] reluctant to move to 
human cells, where the real scientific and commercial payoff 
lies,” mostly because of “lack of funds and the constant threat 
that such an approach could be banned” (Carey, “Stem Cell 
Wars”). This hesitation might also be a result of the plausible 
belief that the citizens have no desire to hear about the latest 
discoveries, or knowledge that their “cult of men in white 
coats” is “tolerated only on its best behavior” (Quimby 162). A 
minority of fanatics’ noisy opposition fuels their apprehension.
 To quell both the animosity and the anxiety, the blinkered 
public must learn to put its faith in the well-educated men and 
women of science in our country and allow them to “call the shots” 
they are perfectly capable of calling regarding stem cell research. 
The value of our currency is based on faith; surely, we can trust 
highly intelligent individuals educated in our own schools and 
universities to make only the best decisions for us. Using history 
as a guide, no one voted when George Washington crossed the 
extensive publicity allotted that particular specialty of the much 
broader field. The blame for this fundamental misattribution 
falls primarily on the scientific community, with the media and 
uninformed individuals also sharing part of the responsibility.
 Our population is constantly inundated with scientific 
claims. With advertisements ranging from scientific-sounding 
shampoo billboards to the assertion that Cheerios are “good 
for your heart” and “can help lower your cholesterol,” members 
of the general public, typically devoid of any scientific 
training beyond high school biology, are “easy prey to the 
pseudoscientific” (Speed Weed 271). Once a declaration such 
as this presents itself, we are all too eager to scramble for the 
“guaranteed” product for weight loss, silky hair, or wrinkle-free 
skin, albeit without any definite comprehension of its actual 
capabilities. Perhaps the hope for an increased quality of life 
drives us toward current fads, or perhaps the mere intrigue of 
the unknown propels us closer to this “miracle” merchandise. 
In a study by the National Science Foundation, “fewer than 
half of American adults polled (47 percent) knew that the 
earth takes one year to orbit the sun,” yet Americans claim 
to be “all ears about science: 90 percent of respondents were 
moderately or very interested in new scientific discoveries” in a 
2002 National Science Board survey (Robinson 68; Speed Weed 
272). This proves a frightening statistic when juxtaposed with 
our real understanding of an area that supposedly intrigues us.
 Many Americans find themselves in a familiar situation 
regarding scientific issues—with a solid opinion but little 
background or knowledge of the science regarding the 
subject—yet we value the opinions of the citizens in this nation, 
and we consider those when formulating policies, especially on 
controversial issues. In a nation where celebrity pet pampering 
and reality television shows have overtaken actual newsworthy 
information, scientists still depend upon society for their 
privileges (Quimby 163). With a discovery as momentous as that 
of somatic cell nuclear transfer, one would believe that it would 
be “front-page news” in American media, yet the coverage has not 
been quite up to par. Human nature causes us to have a difficult 
time admitting when we have fallen behind. We know we should 
have made the breakthrough first—or at least be well on our 
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corporations—with scientific experts in stem cell research leading 
the way—should finance the endeavor (though federal funds 
would certainly be advantageous). Currently, individual states 
and private companies head the field in America. A prominent 
paradigm is California, where citizens “voted to spend $3 billion 
over ten years” in state funds in November 2004 with the passage 
of Proposition 71 (Carey, “Stem-Cell Also”). Connecticut, Illinois, 
and Maryland were quick to follow “with funding initiatives 
of their own” (“AASP”). Similarly, “New Jersey has dedicated 
$11.5 million for its own stem cell institute, with another $380 
million in the works” (Lehrman 41). Also, the aforementioned 
Missouri Stem Cell Research and Cures Initiative passed 
recently. Some states, however, are either unable or unwilling 
to fund stem cell research institutions in their respective 
jurisdictions. This is where private resources enter the scene. 
 Stem cell research advocates need not to worry about 
lack of funding should the industry go entirely private, for a 
plethora of informed philanthropists would earnestly pour 
funds into such a cause. They fear that “state and federal threats 
to ban much of the research are hindering the pace of research 
in America” (Carey, “Stem-Cell Also”). Robert Klein himself 
donated $2.6 million to the California Institute for Regenerative 
Medicine (Lehrman 40). Another example is the Harvard Stem 
Cell Institute, which “has raised $30 million from foundations 
and private donors, and is creating its own stem-cell lines” (Carey, 
“Stem-Cell Also”). Andy Grove, the chairperson of Intel, gave 
the University of California, San Francisco, a $5 million grant 
for the establishment of a Developmental and Stem Cell Biology 
Program (Gershon 929). The resources are indeed available, 
even—and particularly—in the private sector, but this does not 
atone for President Bush’s lack of support for American scientists.
 The President’s discouragement for our men and 
women of science, evident in his restriction on federal funding 
for stem cell research, has caused an inopportune paucity of 
both scientists and funding in the United States. In Korea, 
for example, the estimates of annual spending on embryonic 
stem cell work are “more than $100 million” (Carey, “Stem Cell 
Wars”). The Juvenile Diabetes Research Foundation “now gives 
two thirds of its grant money for embryonic stem cell research 
Delaware, yet the situation ended as well as we had hoped. On 
a more modern note, the Food and Drug Administration does 
not ask people for their opinions when considering approval 
of a new prescription medication. We, in turn, take the word 
of this panel of learned and skilled authorities, for they are 
experts in their area. Stem cell researchers are no different 
concerning their focus than FDA specialists with regard to 
their business, but we habitually accept the latter’s often far-
reaching judgment without question. We should begin to show 
the scientific community in the discipline of stem cell research 
the same respect and allow them to make important decisions 
such as which avenues to chase with research and how best 
to turn their findings into cures and therapies for diseases.
 Since we cannot hope to educate everyone fully on the 
matter, the debate will undoubtedly persist for years, especially in 
the most conservative portions of the United States. As with the 
creation versus evolution debate currently plaguing our nation, 
we will never satisfy both sides. Instead, we should recognize 
the right of the scientific community to “do its job” and pursue 
stem cell research; likewise, the public may exercise its right to 
refuse treatment. One potential consequence, however, would 
certainly be hypocrisy. While “not all conservative Christians 
attack science and reason while gorging on their fruits, […] the 
fanatical fringe surely does” (McManus 161). Invariably, those 
that vehemently contest the research now will be some of the first 
to “take a ticket” as cures and therapies develop for debilitating 
diseases, particularly those that typically affect the elderly, when 
they or their loved ones are forced to choose between a double 
standard and death. By 2040, “an increasing proportion of the 
population in developed countries will be more than 75 years 
old and thinking about how their lives will end” (Singer 41). 
We must act now to aid these individuals in the near future.
 Though the United States House of Representatives 
passed the Stem Cell Research Enhancement Act, legislation 
calling for “increasing federal support of embryonic stem cell 
research” on May 24, 2005, President Bush eventually vetoed 
it, keeping “the stem cell landscape for now […] at status quo” 
(“AASP,” “House” 5). To avoid this controversy over federal public 
funding of research the entire public does not support, private 
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really in the Dark Ages’” (qtd. in Carey, “Stem-Cell Also”). 
We have the potential to become an even more outstanding 
nation because of technological and scientific advances 
such as this; we are the only ones holding ourselves back.
 The controversy over stem cell research—specifically 
embryonic—is nothing short of disastrous, its effects 
comparable to a successful protest of the automobile. We rely 
heavily on our vehicles (many of which come from outside 
the U.S.). A boycott would be not only outrageous but also 
counterproductive, yet we are doing exactly that to stem cell 
researchers. “American ignorance is driving public affairs,” with 
the scientific community, the media, and blasé individuals to 
blame (Robinson 71). We live in a nation where abortion is a 
perfectly legal option in some states, yet we do not give our 
embryonic stem cell researchers a solid foundation on which to 
build cures, treatments, and therapies for diseases from which 
millions of Americans suffer. We only stand to gain from stem 
cell research. By lifting its restrictions, the federal government 
could demonstrate support for our scientists in their efforts to 
“catch up” to the rest of the world, whether publicly or privately 
funded. We, as citizens, should also back the exceptional minds 
behind the research, but we must first take a serious interest. 
Stem cell research could give Humpty-Dumpty another 
chance. To an America sick with illiberality, get well soon.
to foreign scientists” (Carey, “Stem-Cell Also”). Most progress 
today comes from other nations as the United States struggles 
to stay “in the game,” let alone “the unchallenged lead” (Carey, 
“Stem-Cell Also”). In 1998, “nearly 60% of the papers in the 
field were written by U.S. scientists” (Carey, “Stem Cell Wars”). 
As of July 2006, “the percentage [was] below 30%” (Carey, “Stem 
Cell Wars”). Cloning expert Jose Cibelli, professor of animal 
biotechnology at Michigan State University, testifies that the bill 
“is like getting a foot in the door and trying to open it a little, 
when other countries are building huge gates’” (qtd. in Carey, 
“Stem-Cell Also”). Because additional cures to those already 
in existence will undoubtedly take much time to develop, we 
must begin exponential progress immediately. Apparently, we 
are the only powerful nation with the “hang-up” on saving lives.
 The field of stem cell research was “pioneered in the 
U.S. and American researchers were the first to create long-
lived cultures of stem cells, […] in 1998, and the scientific 
community immediately saw vast potential,” yet people are 
now leaving the world’s scientific superpower for treatment 
in countries like Korea, Britain, and Japan (Carey, “Stem-Cell 
Also”). The divergence is due in part to different religious 
beliefs. For example, “in Jewish and Islamic law, a developing 
embryo [does not] become human for forty days—well within 
the time frame in which embryos would be used for therapeutic 
research” (McManus 170). Certainly, this eliminates the 
controversy over embryonic stem cell research for some nations.
 Another important distinction is a generally “more 
liberal and favorable research [environment] for the field” in 
countries such as the United Kingdom, Australia, China, India, 
Israel, Singapore, and Sweden (Gershon 928). Countries like 
Korea and Britain “explicitly allow the creation of new human 
embryos as a source of stem cells,” but this does not make them 
any less “decent” or moral (Carey, “Stem Cell Wars”).The U.S. 
slips to the back of the pack as “foreign labs [announce] a series 
of major breakthroughs, developments that move scientists 
a step closer to cures for a range of illnesses,” and the U.S. 
“could lose out on the eventual commercial applications to 
companies in […] other countries that are rushing ahead with 
the research (Carey, “Stem-Cell Also”). Cibelli states, “We’re 
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